biopharmaceutical
DESCRIPTION
Dear Customer,Stabicon has helped needs of customers in specific areas of the pharmaceutical Analytical Method Development, Validation and Stability study. As the expansion of our analytical services in new technologies and testing methods to help our clients in characterizing future medicines. We understand biology at each of these levels to advance an integrated view of life processes for Biopharmaceuticals. We realize that future medicines (Biopharma) success requires ability to integrate protein testing capabilities which will provide strategic time and cost advantage for Biopharmaceutical sector.We would like to share our presentation on Biopharma solution, to download the presentation please click on the below linkhttps://www.box.net/shared/aboumapp9h9gftunenja/1f7c7a6ef1/rss.xmlIf you are interested in our Biopharma services, it will be a good idea to interact with our technical team/ commercial team for further clarification, looking forward to your response. Thanking you and assuring our best service at all timeRegardsVijayProject DirectorStabicon Life Sciences Pvt LtdMobile: +919591974355/080-41714280www.stabicon.comTRANSCRIPT
![Page 1: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/1.jpg)
1
Biopharmaceutical SolutionBiopharmaceutical Solution
ByBy
Vijay Kumar RankaVijay Kumar Ranka
Stabicon Life Sciences Pvt LtdStabicon Life Sciences Pvt Ltd
![Page 2: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/2.jpg)
2
Topics Topics CoveredCovered ::
I.I. IntroductionIntroduction
II.II. Protein Basic MechanismProtein Basic Mechanism
III.III. Step in Protein Production Step in Protein Production
IV.IV. Identification and characterization techniqueIdentification and characterization technique
V.V. Monitoring protein synthesisMonitoring protein synthesis
VI.VI. Data Processing MethodologyData Processing Methodology
![Page 3: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/3.jpg)
3
IntroductionIntroduction
Chapter Chapter ––II
![Page 4: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/4.jpg)
4
Therapeutic small molecule being dominant for more than 100year Therapeutic small molecule being dominant for more than 100year for for
treatment then why biologics required for therapeutic?treatment then why biologics required for therapeutic?
StabiconStabiconStabiconStabicon
Why???Why???
![Page 5: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/5.jpg)
5
How different they are ?How different they are ?
RequiredRequiredNot RequiredNot RequiredStructural FoldingStructural Folding
EndocytosisEndocytosisMetabolismMetabolismEliminationElimination
LowLowHighHighToxicityToxicity
SpecficSpecficNon Non SpecficSpecficRegulationRegulation
Extensive TrialsExtensive TrialsLimited TrialsLimited TrialsDevelopmentDevelopment
Living organismLiving organismChemical synthesisChemical synthesisProductionProduction
HighHigh--low doselow doseLowLow––high dosehigh doseProduct ActivityProduct Activity
![Page 6: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/6.jpg)
6
What are these?What are these?
�� What are these large molecule or biomolecule and how similar areWhat are these large molecule or biomolecule and how similar are they to they to
human body?human body?
�� What make them so specific and effective?What make them so specific and effective?
�� What is the correlation of large/ biomolecule molecule to livingWhat is the correlation of large/ biomolecule molecule to living machinery?machinery?
![Page 7: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/7.jpg)
7
Mechanism for SignalingMechanism for Signaling
Several types of molecule Several types of molecule
modification are involved in modification are involved in
regulation for a signal regulation for a signal
transfer such as : transfer such as :
glycosylation, acetylation,etcglycosylation, acetylation,etc
![Page 8: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/8.jpg)
8
Effect in the bodyEffect in the body
�� Small molecule rarely elict secondary signaling thus effect prevSmall molecule rarely elict secondary signaling thus effect prevail until drug ail until drug
adhere to the target site whereas in case of large molecule alwaadhere to the target site whereas in case of large molecule always elict an ys elict an
secondary signaling hence effect remain even after the drug is esecondary signaling hence effect remain even after the drug is eliminated. liminated.
![Page 9: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/9.jpg)
9
Protein Basic MechanismProtein Basic Mechanism
Chapter Chapter ––II II
![Page 10: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/10.jpg)
10
Genotype determines phenotypeGenotype determines phenotype
![Page 11: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/11.jpg)
11
Central dogmaCentral dogma
Prokaryotic Cell:Prokaryotic Cell:
DNA DNA –– RNA RNA –– PROTEIN PROTEIN
(Transcription) (Translation)(Transcription) (Translation)
Eukaryotic CellEukaryotic Cell::
DNA DNA –– RNA RNA –– PROTEIN PROTEIN -- PROTEIN MODIFIED PROTEIN MODIFIED
(P(Post Translation)ost Translation)
![Page 12: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/12.jpg)
12
Eukaryotic cellEukaryotic cell
![Page 13: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/13.jpg)
13
Protein StructureProtein Structure
�� PrimaryPrimary
�� SecondarySecondary
�� TertiaryTertiary
�� QuaternaryQuaternary
ACDEFGHIKLMNPQRSTVWY
primary structure
![Page 14: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/14.jpg)
14
ProteomeProteome
GenomeDGenomeD
TranscriptomeDTranscriptomeD
ProteomeProteome
~ 300 modifications~ 300 modifications
GenomicsGenomics
ProteomicsProteomics
GlycosylationGlycosylation
LipidationLipidation
UbiquitinationUbiquitination
Many moreMany more
PhosphorylationPhosphorylation
SugarSugar —
LipidLipid —
PP —
CleavageCleavage
?? —
UbUb —
——
PPPP —
PP —
UbUb —
![Page 15: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/15.jpg)
15
Therapeutic Protein ProductionTherapeutic Protein Production
Chapter Chapter ––IIIIII
![Page 16: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/16.jpg)
16
BiopharmaBiopharma
�� Biopharmaceutical are protein with considerable therapeutic strBiopharmaceutical are protein with considerable therapeutic structural uctural
diversity. They tend to between 100 to 1000 times larger than trdiversity. They tend to between 100 to 1000 times larger than traditional small aditional small
molecule drug .molecule drug .
�� Such complex protein can't be produced using convential chemicaSuch complex protein can't be produced using convential chemical synthesis l synthesis
rather than in a living cell under stringently controlled conditrather than in a living cell under stringently controlled condition.ion.
![Page 17: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/17.jpg)
17
How are these designedHow are these designed
![Page 18: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/18.jpg)
18
Protein FactoryProtein Factory
![Page 19: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/19.jpg)
19
Bioprocessing PhaseBioprocessing Phase
![Page 20: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/20.jpg)
20
Examples of Biologics marketed:Examples of Biologics marketed:
�� InsulinInsulin
�� ImigluceraseImiglucerase
�� GlucagonGlucagon
�� Human Growth HormoneHuman Growth Hormone
�� ErythropoietinErythropoietin
�� GG--CSFCSF
�� InterferonInterferon
![Page 21: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/21.jpg)
21
Chapter –IVChapter Chapter ––IVIV
Protein CharacterizationProtein Characterization
![Page 22: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/22.jpg)
22
Characterization Step:Characterization Step:
�� Intact Mass analysis Intact Mass analysis
�� Primary structure Primary structure -- peptide mappingpeptide mapping
�� Glycan analysisGlycan analysis
�� Amino acid and media analysisAmino acid and media analysis
�� Data processingData processing
![Page 23: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/23.jpg)
23
How to characterize ?How to characterize ?
�� Large scale screening of proteins, their expression, modificatiLarge scale screening of proteins, their expression, modification and interactionon and interaction
by using highby using high--throughput approachesthroughput approaches
![Page 24: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/24.jpg)
24
Characterization Required for Characterization Required for
� Protein identity (mutant protein)Protein identity (mutant protein)
�� Protein quantity (Expression)Protein quantity (Expression)
�� Protein postProtein post--translational modifications (up or down)translational modifications (up or down)
�� Protein structureProtein structure
�� ProteinProtein--protein interactionprotein interaction
�� Protein localizationProtein localization
�� Change in any protein property may cause functional abnormalitChange in any protein property may cause functional abnormality and y and
might be relevant to pathogenesis.might be relevant to pathogenesis.
ToolsTools
�� Protein ArrayProtein Array
�� Mass SpectrometryMass Spectrometry
![Page 25: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/25.jpg)
25
Why Protein by Mass SpectrometryWhy Protein by Mass Spectrometry ??
�� MS can unambiguously identify proteinsMS can unambiguously identify proteins
Gel separated proteinsGel separated proteins
Proteins in mixtureProteins in mixture
Protein: protein associationProtein: protein association
�� Identify precise post translational changesIdentify precise post translational changes
PhosphorylationPhosphorylation
NN-- or Cor C-- terminal modificationterminal modification
Many moreMany more
![Page 26: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/26.jpg)
26
Isolation and characterizationIsolation and characterization
![Page 27: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/27.jpg)
27
Protein Identification TechnologyProtein Identification Technology
Seperation Seperation
Mass AnalysisMass Analysis
Data processing
![Page 28: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/28.jpg)
28
Mass Spectrometry Schematic DiagramMass Spectrometry Schematic Diagram
![Page 29: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/29.jpg)
29
MALDI IonizationMALDI Ionization
Protein or
PeptideMass Spectrometer Mass/Charge
(m/z)Ionization
Solution
Phase
Gas
Phase
Matrix assisted laser desorption ionization (MALDI),
Koichi Tanaka
![Page 30: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/30.jpg)
30
Data Acquisition from MALDIData Acquisition from MALDI--MSIMSI
Alanine, peptide in plasma
m/z = 1474.6Valine, m/z = 1502.7
Alanine
Valine
![Page 31: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/31.jpg)
31
Protein or
PeptideMass Spectrometer Mass/Charge
(m/z)Ionization
Solution
Phase
Gas
Phase
ESI IonizationESI Ionization
Electrospray ionization (ESI), John B Fenn
![Page 32: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/32.jpg)
32
Data Acquisition from ESIData Acquisition from ESI--MSIMSI
![Page 33: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/33.jpg)
33
What is MSE?What is MSE?
![Page 34: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/34.jpg)
34
How to identify a single protein by MS?
Mass/Charge
(m/z)Mass
Digest into many peptides Mass of many
peptides
Peptide mass fingerprinting (PMF)
Mass of many peptide fragmentsBy
Tandem Mass Spectrometry
Single protein identificationSingle protein identification
![Page 35: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/35.jpg)
35
Protein mixture Analysis by LCProtein mixture Analysis by LC--MS/MSMS/MS
Protein mixture
Digestion
Peptides
400 800 1200 1600m/z
MS
MS/MS
10 20 30 min0
HPLC
Database
Searching
LLTTIADAAK
SAGGNYVVFGEAK
EDDVEEAVQAADR
All peptide sequences Identification of many proteins
1 sequencing attempt per 0.5 sec.
3600 sequencing attempts in 30 min.
![Page 36: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/36.jpg)
36
Protein structural SeperationProtein structural Seperation
••An ion in a compactAn ion in a compact--form has a high mobility, and hence shorter drift time, form has a high mobility, and hence shorter drift time,
••The same ion in a more open conformation has a lower mobility, aThe same ion in a more open conformation has a lower mobility, and hence nd hence
a longer drift timea longer drift time
Gate
Detector
Neutral Buffer Gas (-ve force)
Ring Electrodes (Potential Gradient. +ve force)
![Page 37: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/37.jpg)
37
HDMS FOR STRUCTURAL SEPERATION OF ISOMERHDMS FOR STRUCTURAL SEPERATION OF ISOMER
![Page 38: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/38.jpg)
38
IMS separation of peptides and lipidsIMS separation of peptides and lipids
No IMS separation IMS selection of peptides IMS selection of lipids
![Page 39: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/39.jpg)
39
Why Accurate mass?Why Accurate mass?
Intact Protein Mass
Digested Protein Mass
![Page 40: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/40.jpg)
40
Intact Mass AnalysisIntact Mass Analysis
![Page 41: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/41.jpg)
41
How to identify a single protein by MS/MS?How to identify a single protein by MS/MS?
PeptidesPeptides
Theoretical
Spectrum
Database Database
searchingsearching
m/z
Ionization
MS spectrum MS/MS spectrum
Fragmentation
Protein
digestion
Peptide/proteinPeptide/protein
identificationidentification
m/z m/z
200 400 600 800 1000 1200 m/z
K G A FD E L Q
LIFAGKQLEDGR
b ions
1: L
2: LI
3: LIF
4: LIFA
5: LIFAG
6: LIFAGK
7: LIFAGKQ
8: LIFAGKQL
9: LIFAGKQLE
10:LIFAGKQLED
11:LIFAGKQLEDG
y ions
IFAGKQLEDGR:11
FAGKQLEDGR:10
AGKQLEDGR :9
GKQLEDGR :8
KQLEDGR :7
QLEDGR :6
LEDGR :5
EDGR :4
DGR :3
GR :2
R :1
GAF DEL GLI K Q
Q A
![Page 42: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/42.jpg)
42
N & C terminal Ions
Selected Peptides (parent ions) are fragmented in the of a nebulizing neutral gas.
Energy imparted by collision breaks the covalent bond in parent bonds.
y & b-type ions series thus generated can give us the sequence of the peptide
![Page 43: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/43.jpg)
43
Peptide MappingPeptide Mapping
![Page 44: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/44.jpg)
44
Post Translational IdentificationPost Translational Identification
![Page 45: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/45.jpg)
45
GlycoproteinGlycoprotein
![Page 46: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/46.jpg)
46
Monitor the Bioreactor Media Monitor the Bioreactor Media
&&
Protein SynthesisProtein Synthesis
Chapter Chapter –– VV
![Page 47: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/47.jpg)
47
UVUV Aminoacid AnalysisAminoacid Analysis
![Page 48: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/48.jpg)
48
Water PurityWater Purity
![Page 49: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/49.jpg)
49
Amylase Protein ExpressionAmylase Protein Expression
![Page 50: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/50.jpg)
50
E.Coli Lysate AnalysisE.Coli Lysate Analysis
![Page 51: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/51.jpg)
51
Batch AnalysisBatch Analysis
Batch1aBatch1a Batch 2aBBatch 2aB
Batch1bBatch1b Batch2bBatch2b
Batch1cBatch1c Batch2cBatch2cdifference in proteinsdifference in proteins
�� Proteins (to identify and quantify proteins in multiple samplesProteins (to identify and quantify proteins in multiple samples))
How many proteins ?How many proteins ?
The choice of method?The choice of method?
How many samples?How many samples?
How many variability parameter?How many variability parameter?
![Page 52: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/52.jpg)
52
Data processing
Chapter Chapter ––VIVI
![Page 53: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/53.jpg)
53
Data processing Data processing
�� Using a software product designed to facilitate MS and LCMS anaUsing a software product designed to facilitate MS and LCMS analysis of lysis of
biopharmaceutical samplesbiopharmaceutical samples
�� Intact proteins: Intact proteins: Comparison of an entire Comparison of an entire protein(sprotein(s) against a well) against a well--
characterized standard. Identification of differences, and variacharacterized standard. Identification of differences, and variants that nts that
require further investigation (some could be contaminants). require further investigation (some could be contaminants).
�� Peptide map:Peptide map: Comparison of the peptides resulting from a digested Comparison of the peptides resulting from a digested
protein against the peptides from the known standard. Identificaprotein against the peptides from the known standard. Identification of tion of
differences in protein coverage, modifications,differences in protein coverage, modifications,……
![Page 54: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/54.jpg)
54
What software DoesWhat software Does
�� Automates data processing and annotation of experimental resultsAutomates data processing and annotation of experimental results
Produces annotated spectra, chromatograms, coverage maps and tabProduces annotated spectra, chromatograms, coverage maps and tabular ular
datadata
�� Facilitates comparisons between a reference standard and batcheFacilitates comparisons between a reference standard and batches of s of
experimental samplesexperimental samples
�� Outputs include formal reports, figure copy/paste, and tabular Outputs include formal reports, figure copy/paste, and tabular data exportdata export
Frees users to concentrate on important questionsFrees users to concentrate on important questions
![Page 55: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/55.jpg)
55
Intact Protein ChromatogramIntact Protein Chromatogram
![Page 56: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/56.jpg)
56
Protein Charge determinationProtein Charge determination
The theoretical peak
constructed with the isotope
distribution (purple) and the
experimental peak (green) have the same width at half height.
![Page 57: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/57.jpg)
57
Results :Spectra view Results :Spectra view
Stack
Overlay
Mirror
Control :BP_079 non-deglycosylated VICAMAnalyte :BP_092 deglycosylated 19h VICAM
![Page 58: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/58.jpg)
58
Results Spectra view (Intensity filter)Results Spectra view (Intensity filter)
Threshold defined automatically on the spectrahreshold defined automatically
on the spectra
Threshold value Threshold value typed in the tablehe table
Filter applied on Filter applied on the results tableesults table
![Page 59: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/59.jpg)
59
Results: Highlight unique peaksResults: Highlight unique peaks
Unique peaks highlighting
Deglycosylated T022 fragment (analyte only)
Glycosylated T022 fragments (control only)
Control :BP_094 non-deglycosylated digested VICAM
Analyte :BP_097 deglycosylated 2h digested VICAM
![Page 60: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/60.jpg)
60
Result : Peak match data comparison analyte/controlResult : Peak match data comparison analyte/control
![Page 61: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/61.jpg)
61
Results Peak match data for control (glycosylated)Results Peak match data for control (glycosylated)
Percentage of each
glycosylation state in control
Control :BP_079 non-deglycosylated VICAMAnalyte :BP_092 deglycosylated 19h VICAM
![Page 62: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/62.jpg)
62
Results Peak match data for analyte (deglycosylated )Results Peak match data for analyte (deglycosylated )
Percentage of each glycosylation state in analyte
Control :BP_079 non-deglycosylated VICAMAnalyte :BP_092 deglycosylated 19h VICAM
![Page 63: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/63.jpg)
63
Results Peak match data comparison analyte/controlResults Peak match data comparison analyte/control
You can add your own commentsdd your own comments
Control :BP_079 non-deglycosylated VICAMAnalyte :BP_092 deglycosylated 19h VICAM
![Page 64: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/64.jpg)
64
PEPTIDE MAP ANALYSISPEPTIDE MAP ANALYSIS
![Page 65: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/65.jpg)
65
Protein digest Chromatogram Protein digest Chromatogram
Processed Raw
Matched peptides annotation
Control :BP_094 non-deglycosylated digested VICAMAnalyte :BP_097 deglycosylated 2h digested VICAM
![Page 66: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/66.jpg)
66
Results: Results:
Differential viewDifferential view
Control :BP_094 non-deglycosylated digested VICAM
Analyte :BP_097 deglycosylated 2h digested VICAM
![Page 67: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/67.jpg)
67
Protein digest AnalysisProtein digest Analysis
List of the raw data file
Selected analyte compared with the control 2h
Add or remove analyte
Set the selected analyte as control
Reprocess the data with another method
![Page 68: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/68.jpg)
68
Annotation of the peptidesAnnotation of the peptidesAnnotation of the peptides
1:T001
First chain of the protein
Trypsin digestion
First digest product of the chain
1:T001* Modified form of 1:T001
1:T001-002 Missed cleavage between 1:T001 and 1:T002
1:T001-3:T001Disulfide bridge between
1:T001 and 3:T001
![Page 69: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/69.jpg)
69
Results: Results:
Intensity normalisation Intensity normalisation
![Page 70: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/70.jpg)
70
Results: Results:
Highlight unique peaksHighlight unique peaks
Control :BP_094 non-deglycosylated digested VICAM
Analyte :BP_097 deglycosylated 2h digested VICAM
![Page 71: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/71.jpg)
71
Results Results
Coverage mapCoverage map
![Page 72: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/72.jpg)
72
Results Results
Protein digest MassProtein digest Mass
![Page 73: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/73.jpg)
73
ResultsResults
Peak match data comparison analyte/controlPeak match data comparison analyte/control
![Page 74: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/74.jpg)
74
ResultsResults
Peak match data advanced tablePeak match data advanced table
When a mass can correspond to several peptides, the different possibilities can be seen in the advanced view.
![Page 75: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/75.jpg)
75
ResultsResults
Discrimination between two assignmentsDiscrimination between two assignments
The sequence
corresponding to the
fragment 1:T009* of
the LC gave a better
score than the
sequence of 1:T021
If high energy data are available (acquisition with MSE mode), the
fragmentation data can be used to discriminate several assignment for the
same mass.
![Page 76: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/76.jpg)
76
FutureFuture
![Page 77: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/77.jpg)
77
Question???Question???
� Please email to [email protected]
� Write to Stabicon Life Sciences Pvt Ltd
3BM-416,3rd Block,
HRBR Extension,
Bangalore – 560043
Karnataka, India
Phone :+9180 – 41714280/81
![Page 78: Biopharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022042714/554ffe2cb4c905bc138b505c/html5/thumbnails/78.jpg)
78
Thank you
Stabicon Life Sciences Pvt LtdStabicon Life Sciences Pvt Ltd